Marksans Pharma (MARKSANS) — Announcement

📢 Key Event
Q1 FY27 revenue grew 35.6% YoY to INR841 crores with record EBITDA and cash reserves

🔄 What Changed
Revenue growth accelerated to 35.6% YoY and EBITDA margin improved to 25.3% versus prior periods

🔮 What's Next
Europe revenue guidance of INR180 crores for FY27 and target of INR1,000 crores in 3-5 years

💡 Investor Takeaway
Strong growth in Europe and robust cash reserves position Marksans for strategic acquisitions to achieve long-term revenue targets.

Marksans Pharma reported Q1 FY27 revenue of INR841 crores (+35.6% YoY) driven by Europe acquisitions and expansion, with record EBITDA of INR213 crores and PAT of INR159 crores. Cash balance reached INR1,058 crores, supporting strategic acquisitions in Europe as part of a long-term plan to double revenue to INR6,000 crores by 2030.

📄 View Original Announcement (PDF)

📊 Stock Analysis — MARKSANS ✨ Ask AI About This

About Marksans Pharma Limited (MARKSANS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,612.26 Cr P/E: 28.3 ROE: 17.2% ROCE: 23.4% Div Yield: 0.28%

View full MARKSANS stock details →

📡 Get AI alerts when MARKSANS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MARKSANS — Free

💡 Ask AI about this filing

"How will QliniQ and ABCnow acquisitions impact profitability?" "What is the timeline for Germany revenue contribution?" "When will US market expansion plans materialize?"

Ask AI Free →

📊 More MARKSANS filings

See all MARKSANS filings →

🔥 Also filed on 20 August 2026

JSLL Jeena Sikho Lifecare Limited Financial Results ANURAS Anupam Rasayan India Limited Financial Results NIRAJ Niraj Cement Structurals Limited Announcement PNBHOUSING PNB Housing Finance Limited Corporate Action KRONOX Kronox Lab Sciences Limited Announcement SUPRAJIT Suprajit Engineering Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MARKSANS files new disclosures

Track MARKSANS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MARKSANS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd